Page 4 - DUOKOPT BIBLIOBOOK

TABLE OF CONTENTS

Study summary .................................................................................................................................................................................................................................6
Study claims .......................................................................................................................................................................................................................................7
abbreviations .....................................................................................................................................................................................................................................8
Glossary ................................................................................................................................................................................................................................................8

. EASY HANDLING 9

Usability Testing Report for Medical Device. TIM (Transparence et Information du Médicament) ..............................................................11
(According to ISO IEC 62366:2007) Jun 2013
Usability Testing Report for Medical Device. TIM Transparence et Information du Médicament. ............................................................. 13
(According to ISO IEC 62366:2007) Jun 2013

European real-world data about the use of a new delivery system containing a preservative-free multi-dose glaucoma treat-
ment :..................................................................................................................................................................................................................................................37
®
Denis P; et al. European Journal of Ophthalmology.2020 May;0(0) 1-8.

. EFFICACY OF DTFC 49

randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzola-
mide .....................................................................................................................................................................................................................................................51
Boyle JE, et al. Ophthalmology. 1998 Oct;105(10):1945-51.

The safety and efficacy of brinzolamide 1% timolol 0.5% fixed combination versus dorzolamide 2% timolol 0.5% in patients with
OAG or OH ........................................................................................................................................................................................................................................61
Manni G, et al. J Glaucoma. 2009 Apr-May; 18(4):293-300.

Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed
combination in primary open-angle glaucoma .................................................................................................................................................................71
Konstas AG, et al. Eye (Lond). 2012 Jan; 26(1):80 7.

Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and me-
ta-analysis .........................................................................................................................................................................................................................................81
Cheng JW, et al. PLoS One. 2012;7(9):e45079.

. INTEREST OF DTFC IN OPTIC NERVE PERFUSION PERFUSION 95

Effect of Dorzolamide Timolol Combination Versus Timolol 0.5% on Ocular Bloodflow in Patients With Primary Open-angle
Glaucoma .........................................................................................................................................................................................................................................97
Harris A, et al. Am J Ophthalmol 2001; 132:490–495.
Martínez A, et al. Clin Ther. 2008 Jun; 30(6):1120-34.

Visual function, optic nerve structure, and ocular blood flow parameters after 1 year of glaucoma treatment with fixed combina-
tions ...................................................................................................................................................................................................................................................123
Januleviciene I, et al. Eur J Ophthalmol. 2009 Sep-Oct;19(5):790-7.

. EFFICACY OF DTFC ON PROTECTION OF VISUAL FIELD PROGRESSION 135

Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to
timolol 0.5% in primary open-angle glaucoma ..............................................................................................................................................................137
Martinez A, et al. Acta Ophthalmol. 2010: 88: 541–552. 3.